Emily K. Bergsland, MD
Ernest Rosenbaum, MD, Endowed Chair in Medical Oncology, UCSF
Professor of Clinical Medicine, UCSF; Associate Director for Education, Helen Diller Family Comprehensive Cancer Center
My research efforts are focused on the development and testing of novel, biologically based therapies for gastrointestinal malignancies, with an emphasis on neuroendocrine tumors (NETs). I am co-chair of the GI Oncology site committee and an active member of the Phase I committee at UCSF. Nationally, I am co-chair of the Neuroendocrine Tumor Task Force of the National Cancer Institute (NCI) Gastrointestinal Steering Committee, a member of the NCCN Neuroendocrine Tumors Guidelines Panel, a member of the Board of Directors for the North American Neuroendocrine Tumor Society (NANETS), and co-chair of the 8th edition AJCC Expert Panel on staging for NETs. I am also study chair for ALLIANCE A021202 (an ongoing randomized Phase II trial of pazopanib vs. placebo in patients with progressive carcinoid tumors). My current research is focused on publishing the results of three completed investigator-initiated Phase II clinical trials in NETs (a. FOLFOX/bevacizumab, b. everolimus plus erlotinib, and c. axitinib), fostering several collaborations with laboratory-based colleagues, and taking advantage of a fully annotated outcomes database (established in 2010 and encompassing 600+ NET patients treated at UCSF since 2004).
University of Wisconsin, B.S., 1985, Biochemistry and Molecular Biology
University of Minnesota, M.D., 1982